12/15/2023 | PV | Geron amends loan facility, increases newly drawn tranche to $30 million
|
3/13/2023 | PV | Geron details status of term loan facility with Silicon Valley
|
6/30/2022 | PV | Geron ups loan facility with Hercules, Silicon Valley to $125 million
|
10/1/2020 | PV | Geron enters $75 million loan facility with Hercules, Silicon Valley
|
8/28/2015 | PP | Geron arranges $50 million at-the-market offering of common stock
|
10/9/2012 | PP | Geron negotiates $50 million at-the-market issuance sales agreement
|
7/3/2012 | CVIGPF | Geron files $200 million shelf covering stock, debt and preferreds
|
8/1/2011 | PP | Geron secures $24.85 million through five-year loan, warrant agreement
|
9/10/2009 | PP | New Issue: Geron to sell approximately $3.6 million of shares in direct placement
|
9/10/2009 | PP | Market Commentary: AgFeed inks $50 million credit line; Geron gets capital infusion; MacDonald settles unit sale
|
7/9/2009 | CVIG | Geron files $250 million shelf covering warrants, debt, preferreds
|
12/15/2006 | PP | Market Commentary: Enzo Biochem secures $46 million from direct placement; NovaDel to settle $14.24 million stock sale
|
12/14/2006 | PP | New Issue: Geron secures $40 million from direct placement of stock
|
12/14/2006 | PP | Market Commentary: Linn Energy pockets $360 million from PIPE; Geron gears up to close $40 million stock offering
|
11/8/2006 | BT | Geron says telomerase activation program has equal potential to cancer program
|
11/8/2006 | BT | Market Commentary: Catalyst higher on debut; Hollis-Eden off 19% on PIPE; stem cell names better; Trimeris rises 23%
|
10/30/2006 | BT | Geron records $9.8 million net loss for the third quarter, says revenues up slightly
|
9/6/2006 | BT | Geron, Advanced Cell settle patent suit
|
9/6/2006 | BT | Market Commentary: Genta plummets another 41%; Genomic Health falls 17%; Cell Therapeutics up 8%; Anadys up
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
8/21/2006 | BT | Geron: Data shows TAT0002 enhances function of key immune cells in HIV/AIDS patients
|
8/7/2006 | BT | Geron, University of Edinburgh to develop stem-cell derived cell types
|
8/4/2006 | BTCV | Geron files $250 million shelf registration
|
7/31/2006 | BT | Geron reports $9.3 million second quarter net loss
|
7/19/2006 | BT | Geron says its stem cell-based therapeutic product effective in treating mild spinal cord injury in rats
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
7/13/2006 | BT | Geron's novel method reduces number of steps, cost in synthesizing monomer building blocks
|
7/5/2006 | BT | Geron leveraging its human embryonic stem cell platform, develops new products
|
6/29/2006 | BT | Invitrogen licenses stem-cell intellectual property from Geron
|
6/29/2006 | BT | Market Commentary: Invitrogen, Geron rise on pact; other stem cell names higher; Keryx up 8%; Nabi up over 2%
|
6/22/2006 | BT | Geron, Corning to develop synthetic surfaces for growth of embryonic stem cells
|
6/15/2006 | BT | Geron to appeal European Patent Office's decision to cancel three claims
|
6/14/2006 | BT | Pharmexa prevails in opposition to Geron's European patent
|
5/15/2006 | BT | Geron, TA Therapeutics' new data support use of small molecule telomerase activator in HIV/AIDS
|
4/28/2006 | BT | Geron first-quarter operating revenues rise; net loss shrinks to $9 million
|
4/26/2006 | BT | Geron issued patent for production of insulin-secreting cells from human embryonic stem cells
|
4/26/2006 | BT | Market Commentary: Inspire trial launch brings buyers; Avigen players hopeful; Applera units mixed; LifeCell lifted 15%
|
4/6/2006 | BT | Geron makes multiple telomerase presentations at AACR meeting
|
4/3/2006 | BT | Geron starts clinical trial for telomerase inhibitor drug in solid tumors
|
4/3/2006 | BT | Market Commentary: Epix up 21% on Predix buy; Incyte falls 41%; Medarex off; Inhibitex plunges 66%; StemCells dives
|
3/27/2006 | BT | Geron, University of Oxford enter into agreement for stem-cell research
|
2/22/2006 | BT | Geron study shows cardiomyocytes a promising treatment for heart attack
|
2/15/2006 | BT | Geron licenses MaxCyte's cell loading technology for use in cancer vaccine
|
2/13/2006 | BT | Geron, Cambrex announce manufacturing arrangement for cancer vaccine Grnvac1
|
2/7/2006 | BT | Geron announces launch of telomerase-immortalized cell line
|
2/6/2006 | BT | Market Commentary: OSI Pharma players debate new policy; Serono slips as 'for sale' sign stands; CuraGen gains 11%
|
2/3/2006 | BT | Geron's telomerase activators increase immune system efficacy during in vitro HIV/AIDS study
|
2/2/2006 | BT | Geron defends telomerase patents against Pharmexa
|
1/27/2006 | BT | Geron announces improved production method for embryonic stem cells
|
12/12/2005 | BT | Geron's GRN163L shows anti-tumor activity in preclinical studies
|
9/20/2005 | BT | Geron greenshoe fully exercised, augmenting stock sale to $62.1 million
|
9/19/2005 | BT | Market Commentary: Viacell plunges on suspending study; StemCells rises on new filing; Inex drops on note demand
|
9/16/2005 | BT | New Issue: Geron raises $72 million gross in follow-on, Merck transactions at $9 vs. $9.99 close
|
9/16/2005 | BT | Market Commentary: Meridian Biosciences slips in spot deal; Myogen, Geron deals show improved reception
|
9/15/2005 | BT | Market Commentary: Myogen, Geron follow-ons at bat; ViroPharma up; Advancis almost doubles; GTx launches new deal
|
9/14/2005 | BT | Market Commentary: Progenics off on spot sale; profits taken on Celgene rise; Cubist off; Access dives on bankruptcy fears
|
9/13/2005 | BT | Market Commentary: Immunomedics up; OSI rebounds; Celgene retreats; Protein Design Labs, Novavax, Cephalon all up
|
9/12/2005 | BT | Geron plans follow-on sale of 6 million shares Thursday via UBS
|
9/12/2005 | BT | Geron joins Myogen for Thursday; Cell Genesys up on back of Geron; OSI Pharma plummets on Tarceva
|
7/29/2005 | BT | Market Commentary: Advanced Life Sciences, Avalon IPOs delayed; ZymoGenetics on deck for Wed; stem cell names rise
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
6/22/2005 | BT | Market Commentary: HemoSense cuts IPO range again; CV Therapeutics offerings emerge; Eyetech zooms on boosted outlook
|
6/17/2005 | BT | Market Commentary: Mylan Labs bond deal surfaces; Vertex up, Merck lags; Genentech rises; stem cell names watched
|
4/25/2005 | PP | New Issue: Geron raises $4 million in direct placement of stock
|
4/25/2005 | PP | Market Commentary: Matrix raises $30 million in convertible notes; resources continue to make comeback
|
11/11/2004 | PP | New Issue: Geron gets agreements for $40 million in direct placement of stock
|
1/29/2002 | CVHY | Geron files $150 million debt, preferred, stock, convertibles shelf
|